French Health Authority Modifies Acomplia Medical Notice
Friday July 11st, 2008 / 12h22
PARIS -(Dow Jones)- The French health authority Afssaps said Friday it has modified the summary of characteristics of the Sanofi-Aventis (SNY) marketed drug Acomplia. The analysis of statistics acquired over the last year confirms the safety profile of the drug, notably concerning the risk of side effects linked to depression, Afssaps said. Afssaps noted that the side effects appear mainly at the beginning of the treatment. The summary of characteristics of Accomplia now includes new warnings and monitoring recommendations, Afssaps said. Afssaps Web site: www.afssaps.sante.fr -By William Horobin, Dow Jones Newswires; +33 1 4017 1740; william.horobin@dowjones.com Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http://www.djnewsplus.com/al?rnd=drIHRBj%2B6VfZ9WYRcX%2F%2B1A%3D%3D. You can use this link on the day this article is published and the following day.
Sanofi-Aventis est le 1er groupe pharmaceutique européen. Le CA par famille de produits se répartit comme suit : - produits pharmaceutiques (90,1%) :...
